Hypermarcas (HYPMY) Projected to Announce Earnings on Wednesday

Posted by Brian Himes on Nov 4th, 2026

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) is anticipated to announce its results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of $0.14 per share and revenue of $450.75 million for the quarter.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, analysts expect Hypermarcas to post $0.50 EPS for the current fiscal year and $0.58 EPS for the next fiscal year.

Hypermarcas Stock Performance

Shares of OTCMKTS:HYPMY opened at $3.83 on Wednesday. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 7.94 and a beta of 0.78. The firm’s 50 day simple moving average is $4.65 and its 200 day simple moving average is $4.43. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26. Hypermarcas has a fifty-two week low of $3.39 and a fifty-two week high of $5.77.

Analysts Set New Price Targets

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Get Our Latest Research Report on Hypermarcas

Hypermarcas Company Profile

(Get Free Report)

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.